ZEVRA THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ZEVRA THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $0 | Mar 16, 2016 |
| FY2015 | Sep 30, 2015 | $0 | Mar 16, 2016 |
| FY2015 | Jun 30, 2015 | $0 | Mar 16, 2016 |
| FY2015 | Mar 31, 2015 | $0 | Mar 16, 2016 |
| FY2015 | Dec 31, 2014 | $0 | Mar 16, 2016 |
| FY2015 | Sep 30, 2014 | $0 | Mar 16, 2016 |
| FY2015 | Jun 30, 2014 | $0 | Mar 16, 2016 |
| FY2015 | Mar 31, 2014 | $0 | Mar 16, 2016 |
| FY2015 | Dec 31, 2013 | $0 | Mar 16, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.23M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($105.51M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($46.05M) | Mar 12, 2025 |
| FY2023 | Sep 30, 2023 | ($10.37M) | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | ($2.57M) | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | ($13.22M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($26.77M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($8.56M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($12.76M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($24.52M) | Mar 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.94M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($87.00M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($49.60M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($42.57M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.73M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($5.61M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.34M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($55.90M) | Feb 28, 2020 |
| FY2017 | Dec 31, 2017 | ($8.15M) | Mar 30, 2018 |
| FY2017 | Sep 30, 2017 | ($9.61M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $10.16M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $8.84M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $19.42M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $41.76M | Feb 28, 2020 |
| FY2017 | Dec 31, 2017 | $5.54M | Mar 30, 2018 |
| FY2017 | Sep 30, 2017 | $6.29M | Mar 30, 2018 |
| FY2017 | Jun 30, 2017 | $4.65M | Mar 30, 2018 |
| FY2017 | Mar 31, 2017 | $4.11M | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $7.96M | Mar 30, 2018 |
| FY2017 | Sep 30, 2016 | $4.29M | Mar 30, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.62M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $54.87M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $34.31M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $15.04M | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.60M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($69.67M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($33.54M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($18.72M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.44M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($1.94M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($23.74M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($54.20M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($33.10M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($29.77M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $835.0K | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $296.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $93.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $102.0K | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $33.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $26.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $21.0K | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $181.0K | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $643.0K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.73M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $178.13M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $172.33M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $115.34M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $132.94M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $11.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $10.51M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $26.75M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $52.46M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $84.89M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.07M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $138.46M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $110.46M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $40.22M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.82M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $77.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $84.96M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $93.31M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $109.97M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $103.58M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.66M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $39.67M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $61.86M | Mar 9, 2026 |
| FY2023 | Sep 30, 2023 | $61.52M | Apr 1, 2024 |
| FY2024 | Dec 31, 2022 | $75.12M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $101.66M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($66.41M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | ($74.46M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($66.57M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | ($57.52M) | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.70M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $4.70M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $4.70M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($422.06M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($505.29M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($399.78M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($353.73M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($267.03M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($258.47M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($245.71M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($221.19M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($164.73M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($121.34M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.41M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $33.79M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $43.05M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $65.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $112.35M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $4.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.22M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $18.41M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $10.87M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $16.76M | Mar 30, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.93M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $59.50M | Mar 9, 2026 |
| FY2020 | Dec 31, 2020 | $67.66M | Mar 12, 2021 |
| FY2020 | Dec 31, 2019 | $77.34M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $81.44M | Feb 28, 2020 |
| FY2017 | Dec 31, 2017 | $92.73M | Mar 30, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 31, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 30, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 30, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 30, 2018 |
| FY2017 | Mar 31, 2017 | (1) | Mar 30, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 9, 2026 |
| FY2021 | Dec 31, 2021 | (2) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | (3) | Mar 31, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 30, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 30, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 30, 2018 |
| FY2017 | Mar 31, 2017 | (1) | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 30, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Mar 30, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.85M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 53.67M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 41.53M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | 34.54M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | 35.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | 4.54M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | 2.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | 1.65M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | 14.66M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 14.65M | Mar 1, 2019 |